Monoclonal antibodies (mAb) are central to the treatment of several types of malignancy. However, these reagents are subject to particular types of resistance. Several resistance mechanisms are regulated by the inhibitory FcγRIIB. We recently developed mAbs to block FcγRIIB and provided in vivo proof-of-concept for their ability to overcome FcγRIIB-mediated resistance.
CITATION STYLE
Roghanian, A., Cragg, M. S., & Frendéus, B. (2016). Resistance is futile: Targeting the inhibitory FcγRIIB (CD32B) to maximize immunotherapy. OncoImmunology, 5(2). https://doi.org/10.1080/2162402X.2015.1069939
Mendeley helps you to discover research relevant for your work.